A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects

Subjects will be randomised to receive a single dose of NNC 0148-0000-0362 orally within each dose group

As an active comparator, one standard dose will be given subcutaneously (s.c., under the skin) within each dose group

Subjects will receive a single dose of oral placebo within each dose group

Single low dose administered orally in randomised order on three dosing visits separated by a wash-out period

Single high dose administered i.v. in randomised order on three dosing visits separated by a wash-out period

Single high dose administered orally in randomised order on three dosing visits separated by a wash-out period